^
BIOMARKER:
MSI-H/dMMR
i
Other names: MSI-H, Microsatellite instability - high, dMMR
›
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
nivolumab + ipilimumab Sensitive: A1 - Approval
Clin Colorectal Cancer - 2 weeks
|
nivolumab + ipilimumab Sensitive: A1 - Approval
Clin Colorectal Cancer - 2 weeks
|
MSI-H/dMMR
|
Endometrial Cancer
|
MSI-H/dMMR
|
Endometrial Cancer
|
pembrolizumab Sensitive: A2 - Guideline
J Clin Oncol - 2 weeks
|
pembrolizumab Sensitive: A2 - Guideline
J Clin Oncol - 2 weeks
|
MSI-H/dMMR
|
Solid Tumor
|
MSI-H/dMMR
|
Solid Tumor
|
dostarlimab Sensitive: A1 - Approval
|
dostarlimab Sensitive: A1 - Approval
|
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
MSI-H/dMMR
|
Solid Tumor
|
MSI-H/dMMR
|
Solid Tumor
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
MSI-H/dMMR
|
Endometrial Cancer
|
MSI-H/dMMR
|
Endometrial Cancer
|
dostarlimab Sensitive: A1 - Approval
|
dostarlimab Sensitive: A1 - Approval
|
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
MSI-H/dMMR
|
Peritoneal Cancer
|
MSI-H/dMMR
|
Peritoneal Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Small Intestinal Carcinoma
|
MSI-H/dMMR
|
Small Intestinal Carcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Esophageal Cancer
|
MSI-H/dMMR
|
Esophageal Cancer
|
dostarlimab Sensitive: A2 - Guideline
|
dostarlimab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
dostarlimab Sensitive: A2 - Guideline
|
dostarlimab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Colon Cancer
|
MSI-H/dMMR
|
Colon Cancer
|
CAPOX Sensitive: A2 - Guideline
|
CAPOX Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Colon Cancer
|
MSI-H/dMMR
|
Colon Cancer
|
FOLFOX Sensitive: A2 - Guideline
|
FOLFOX Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Prostate Cancer
|
MSI-H/dMMR
|
Prostate Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Fallopian Tube Cancer
|
MSI-H/dMMR
|
Fallopian Tube Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Maxillary Sinus Carcinoma
|
MSI-H/dMMR
|
Maxillary Sinus Carcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Penile Cancer
|
MSI-H/dMMR
|
Penile Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Endometrial Cancer
|
MSI-H/dMMR
|
Endometrial Cancer
|
pembrolizumab + lenvatinib Sensitive: A2 - Guideline
|
pembrolizumab + lenvatinib Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Small Intestinal Carcinoma
|
MSI-H/dMMR
|
Small Intestinal Carcinoma
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Small Intestinal Carcinoma
|
MSI-H/dMMR
|
Small Intestinal Carcinoma
|
pembrolizumab + ipilimumab Sensitive: A2 - Guideline
|
pembrolizumab + ipilimumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Small Intestinal Carcinoma
|
MSI-H/dMMR
|
Small Intestinal Carcinoma
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Ovarian Cancer
|
MSI-H/dMMR
|
Ovarian Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Germ Cell Tumors
|
MSI-H/dMMR
|
Germ Cell Tumors
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Gastroesophageal Junction Adenocarcinoma
|
MSI-H/dMMR
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
pembrolizumab + ipilimumab Sensitive: A2 - Guideline
|
pembrolizumab + ipilimumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Biliary Tract Cancer
|
MSI-H/dMMR
|
Biliary Tract Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Rectal Cancer
|
MSI-H/dMMR
|
Rectal Cancer
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Neuroendocrine Tumor
|
MSI-H/dMMR
|
Neuroendocrine Tumor
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Gastric Cancer
|
MSI-H/dMMR
|
Gastric Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Pancreatic Adenocarcinoma
|
MSI-H/dMMR
|
Pancreatic Adenocarcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Cervical Cancer
|
MSI-H/dMMR
|
Cervical Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Chordoma
|
MSI-H/dMMR
|
Chordoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Ewing Sarcoma
|
MSI-H/dMMR
|
Ewing Sarcoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Osteosarcoma
|
MSI-H/dMMR
|
Osteosarcoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Breast Cancer
|
MSI-H/dMMR
|
Breast Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Rectal Cancer
|
MSI-H/dMMR
|
Rectal Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Rectal Cancer
|
MSI-H/dMMR
|
Rectal Cancer
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Testicular Cancer
|
MSI-H/dMMR
|
Testicular Cancer
|
cemiplimab Sensitive: A2 - Guideline
|
cemiplimab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Vulvar Cancer
|
MSI-H/dMMR
|
Vulvar Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Biliary Tract Cancer
|
MSI-H/dMMR
|
Biliary Tract Cancer
|
dostarlimab Sensitive: A2 - Guideline
|
dostarlimab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
HCC
|
MSI-H/dMMR
|
HCC
|
dostarlimab Sensitive: A2 - Guideline
|
dostarlimab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Gastric Cancer
|
MSI-H/dMMR
|
Gastric Cancer
|
dostarlimab Sensitive: A2 - Guideline
|
dostarlimab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Gastroesophageal Junction Adenocarcinoma
|
MSI-H/dMMR
|
Gastroesophageal Junction Adenocarcinoma
|
dostarlimab Sensitive: A2 - Guideline
|
dostarlimab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Solid Tumor
|
MSI-H/dMMR
|
Solid Tumor
|
KN035 Sensitive: B - Late Trials
|
KN035 Sensitive: B - Late Trials
|
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
KN035 Sensitive: B - Late Trials
|
KN035 Sensitive: B - Late Trials
|
MSI-H/dMMR
|
Gastric Cancer
|
MSI-H/dMMR
|
Gastric Cancer
|
KN035 Sensitive: B - Late Trials
|
KN035 Sensitive: B - Late Trials
|
MSI-H/dMMR
|
Solid Tumor
|
MSI-H/dMMR
|
Solid Tumor
|
nivolumab Sensitive: C1 - Off-label
|
nivolumab Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
RCC
|
MSI-H/dMMR
|
RCC
|
dostarlimab Sensitive: C1 - Off-label
|
dostarlimab Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Gallbladder Cancer
|
MSI-H/dMMR
|
Gallbladder Cancer
|
dostarlimab Resistant: C1 - Off-label
|
dostarlimab Resistant: C1 - Off-label
|
MSI-H/dMMR
|
Breast Cancer
|
MSI-H/dMMR
|
Breast Cancer
|
dostarlimab Sensitive: C1 - Off-label
|
dostarlimab Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Ovarian Cancer
|
MSI-H/dMMR
|
Ovarian Cancer
|
dostarlimab Sensitive: C1 - Off-label
|
dostarlimab Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Adrenal Cortex Carcinoma
|
MSI-H/dMMR
|
Adrenal Cortex Carcinoma
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Uterine Cancer
|
MSI-H/dMMR
|
Uterine Cancer
|
nivolumab Sensitive: C1 - Off-label
|
nivolumab Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Gastric Cancer
|
MSI-H/dMMR
|
Gastric Cancer
|
nivolumab Sensitive: C1 - Off-label
|
nivolumab Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Gallbladder Cancer
|
MSI-H/dMMR
|
Gallbladder Cancer
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Prostate Cancer
|
MSI-H/dMMR
|
Prostate Cancer
|
nivolumab Sensitive: C1 - Off-label
|
nivolumab Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Cervical Cancer
|
MSI-H/dMMR
|
Cervical Cancer
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
GBM
|
MSI-H/dMMR
|
GBM
|
nivolumab Sensitive: C1 - Off-label
|
nivolumab Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Cholangiocarcinoma
|
MSI-H/dMMR
|
Cholangiocarcinoma
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Gastrointestinal Cancer
|
MSI-H/dMMR
|
Gastrointestinal Cancer
|
nivolumab Sensitive: C1 - Off-label
|
nivolumab Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Gastrointestinal Cancer
|
MSI-H/dMMR
|
Gastrointestinal Cancer
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Urothelial Cancer
|
MSI-H/dMMR
|
Urothelial Cancer
|
nivolumab Sensitive: C1 - Off-label
|
nivolumab Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Urothelial Cancer
|
MSI-H/dMMR
|
Urothelial Cancer
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Endometrial Cancer
|
MSI-H/dMMR
|
Endometrial Cancer
|
INCMGA0012 Sensitive: C2 – Inclusion Criteria
|
INCMGA0012 Sensitive: C2 – Inclusion Criteria
|
MSI-H/dMMR
|
Solid Tumor
|
MSI-H/dMMR
|
Solid Tumor
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
MSI-H/dMMR
|
Endometrial Cancer
|
MSI-H/dMMR
|
Endometrial Cancer
|
avelumab Sensitive: C2 – Inclusion Criteria
|
avelumab Sensitive: C2 – Inclusion Criteria
|
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
regorafenib Sensitive: C2 – Inclusion Criteria
|
regorafenib Sensitive: C2 – Inclusion Criteria
|
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
XmAb717 Sensitive: C2 – Inclusion Criteria
|
XmAb717 Sensitive: C2 – Inclusion Criteria
|
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
avelumab Sensitive: C2 – Inclusion Criteria
|
avelumab Sensitive: C2 – Inclusion Criteria
|
MSI-H/dMMR
|
Gastric Cancer
|
MSI-H/dMMR
|
Gastric Cancer
|
CP-675206 Sensitive: C2 – Inclusion Criteria
|
CP-675206 Sensitive: C2 – Inclusion Criteria
|
MSI-H/dMMR
|
Gastric Cancer
|
MSI-H/dMMR
|
Gastric Cancer
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
MSI-H/dMMR
|
Solid Tumor
|
MSI-H/dMMR
|
Solid Tumor
|
avelumab Sensitive: C2 – Inclusion Criteria
|
avelumab Sensitive: C2 – Inclusion Criteria
|
MSI-H/dMMR
|
Solid Tumor
|
MSI-H/dMMR
|
Solid Tumor
|
tislelizumab Sensitive: C2 – Inclusion Criteria
|
tislelizumab Sensitive: C2 – Inclusion Criteria
|
MSI-H/dMMR
|
Solid Tumor
|
MSI-H/dMMR
|
Solid Tumor
|
BMS-986016 Sensitive: C2 – Inclusion Criteria
|
BMS-986016 Sensitive: C2 – Inclusion Criteria
|
MSI-H/dMMR
|
Gastric Cancer
|
MSI-H/dMMR
|
Gastric Cancer
|
tislelizumab Sensitive: C2 – Inclusion Criteria
|
tislelizumab Sensitive: C2 – Inclusion Criteria
|
MSI-H/dMMR
|
Gastric Cancer
|
MSI-H/dMMR
|
Gastric Cancer
|
sintilimab Sensitive: C2 – Inclusion Criteria
|
sintilimab Sensitive: C2 – Inclusion Criteria
|
MSI-H/dMMR
|
Rectal Cancer
|
MSI-H/dMMR
|
Rectal Cancer
|
sintilimab Sensitive: C2 – Inclusion Criteria
|
sintilimab Sensitive: C2 – Inclusion Criteria
|
MSI-H/dMMR
|
Solid Tumor
|
MSI-H/dMMR
|
Solid Tumor
|
HX008 Sensitive: C2 – Inclusion Criteria
|
HX008 Sensitive: C2 – Inclusion Criteria
|
MSI-H/dMMR
|
Solid Tumor
|
MSI-H/dMMR
|
Solid Tumor
|
HLX10 Sensitive: C2 – Inclusion Criteria
|
HLX10 Sensitive: C2 – Inclusion Criteria
|
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
toripalimab Sensitive: C2 – Inclusion Criteria
|
toripalimab Sensitive: C2 – Inclusion Criteria
|
MSI-H/dMMR
|
Gastroesophageal Junction Adenocarcinoma
|
MSI-H/dMMR
|
Gastroesophageal Junction Adenocarcinoma
|
sintilimab Sensitive: C2 – Inclusion Criteria
|
sintilimab Sensitive: C2 – Inclusion Criteria
|
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
MSI-H/dMMR
|
Solid Tumor
|
MSI-H/dMMR
|
Solid Tumor
|
M7824 Resistant: C3 – Early Trials
|
M7824 Resistant: C3 – Early Trials
|
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
bevacizumab Resistant: C3 – Early Trials
|
bevacizumab Resistant: C3 – Early Trials
|
MSI-H/dMMR
|
Endometrial Adenocarcinoma
|
MSI-H/dMMR
|
Endometrial Adenocarcinoma
|
AZD1775 Sensitive: C3 – Early Trials
|
AZD1775 Sensitive: C3 – Early Trials
|
MSI-H/dMMR
|
Prostate Cancer
|
MSI-H/dMMR
|
Prostate Cancer
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
5-fluorouracil + oxaliplatin Resistant: C3 – Early Trials
|
5-fluorouracil + oxaliplatin Resistant: C3 – Early Trials
|
MSI-H/dMMR
|
Prostate Cancer
|
MSI-H/dMMR
|
Prostate Cancer
|
paclitaxel + docetaxel + etoposide IV Sensitive: C3 – Early Trials
|
paclitaxel + docetaxel + etoposide IV Sensitive: C3 – Early Trials
|
MSI-H/dMMR
|
Biliary Tract Cancer
|
MSI-H/dMMR
|
Biliary Tract Cancer
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
MSI-H/dMMR
|
Solid Tumor
|
MSI-H/dMMR
|
Solid Tumor
|
camrelizumab Sensitive: C3 – Early Trials
|
camrelizumab Sensitive: C3 – Early Trials
|
MSI-H/dMMR
|
Gastric Cancer
|
MSI-H/dMMR
|
Gastric Cancer
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
MSI-H/dMMR
|
Gastric Cancer
|
MSI-H/dMMR
|
Gastric Cancer
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
MSI-H/dMMR
|
Prostate Cancer
|
MSI-H/dMMR
|
Prostate Cancer
|
pembrolizumab + BBI608 Sensitive: C3 – Early Trials
|
pembrolizumab + BBI608 Sensitive: C3 – Early Trials
|
